ST elevation myocardial infarction
Drug research and approvals for ST elevation myocardial infarction: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 130 studies of ST elevation myocardial infarction are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 130
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial InfarctionNCT07947498 · Not applicable · Chungnam National University Hospital · starts Aug 2, 2024
- Evaluation of the Predictive Value of Microemboli Detected by Robotic Transcranial Doppler (TCD) for the Occurrence of…NCT07932080 · Not applicable · CHC Montlegia · starts Dec 1, 2026
- Reducing Slow/No-Reflow With Prophylactic High-Dose Intracoronary Adenosine Protocol in ST-Elevation Myocardial…NCT07898696 · Not applicable · Prof Muzaffar Ali Zahidi · starts Aug 14, 2026
- Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following…NCT07890168 · Not reported · Sohag University · starts Sep 1, 2026
- Analysis of Life-threatening ARrhythMias After Acute Coronary SyndromeNCT07824050 · Not reported · Catharina Ziekenhuis Eindhoven · starts Jul 14, 2026
- Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary SyndromeNCT07824323 · Phase 4 · Taipei Medical University Hospital · starts Aug 26, 2026
- Smartphone AI Assistance for Prehospital ECG InterpretationNCT07810686 · Not applicable · École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · starts Sep 2, 2026
- A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting…NCT07806370 · Not reported · Xijing Hospital · starts Jan 1, 2019
- SMARTwatch for the Diagnosis of ST-segment Elevation Myocardial Infarction in Patients With Chest PainNCT07780942 · Not reported · Hospital General Universitario Santa Lucia · starts Aug 14, 2026
Approved 1
- ReteplaseTissue-type plasminogen activator exogenous protein
Phase 3 12 of 21
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- PrasugrelPurinergic receptor P2Y12 antagonist
- ValsartanType-1 angiotensin II receptor antagonist
- ClopidogrelPurinergic receptor P2Y12 antagonist
- TenecteplaseTissue-type plasminogen activator exogenous protein
- AtorvastatinHMG-CoA reductase inhibitor
- ColchicineTubulin inhibitor
- AspirinCyclooxygenase inhibitor
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- EnalaprilAngiotensin-converting enzyme inhibitor
- MetoprololBeta-1 adrenergic receptor antagonist
- Enoxaparin sodiumAntithrombin-III activator
Phase 2 12 of 17
- AdenosineAdenosine receptor agonist
- Nitric oxideSoluble guanylate cyclase activator
- Nitrous acid
- NitroprussideSoluble guanylate cyclase activator
- Sodium iodide
- UrokinaseUrokinase-type plasminogen activator exogenous protein
- Epoetin alfaErythropoietin receptor agonist
- EptifibatideIntegrin alpha-IIb/beta-3 inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- CangrelorPurinergic receptor P2Y12 antagonist
- EvolocumabSubtilisin/kexin type 9 inhibitor
- RoxadustatHypoxia-inducible factor prolyl hydroxylase inhibitor
Phase 1 or earlier 2
- NivolumabProgrammed cell death protein 1 inhibitor
- Cenderitide
How its trials ended
559 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 103 whose ending is known, 43% met their primary endpoint, 19% missed it and 38% stopped early.
- Status unknown16730%
- Completed, result not reported15828%
- Ongoing13123%
- Met its primary endpoint448%
- Stopped: other or unclear254%
- Missed its primary endpoint204%
- Stopped: enrollment or feasibility81%
- Stopped: sponsor or business decision41%
- Stopped: safety1<1%
- Stopped: funding1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA